baber/WOPTO huggingface dataset:
Patent SG-169326-A1 (SG)
Title: Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins
Inventor: BERLIN JACOB
Filed: 2006-12-18
Abstract: The invention relates to ruthenium alkylidene complexes having an N- heterocyclic carbene ligand comprising a 5-membered heterocyclic ring having a carbenic carbon atom and at least one nitrogen atom contained within the 5- membered heterocyclic ring, wherein the nitrogen atom is directly attached to the carbenic carbon atom and is substituted by a phenyl ring, and wherein the phenyl ring has a hydrogen at either or both ortho positions and is substituted and at least one orthq or meta position. The invention also relates to an olefin metathesis reactions and particularly to the preparation of tetra-substituted cyclic olefins via a ring-closing metathesis.
Patent SG-174037-A1 (SG)
Title: Method and device for treating substrates andcorresponding nozzle unit
Inventor: BRANZ KARSTEN
Filed: 2005-10-28
Abstract: AbstractMETHOD AND DEVICE FOR TREATING SUBSTRATES AND CORRESPONDING NOZZLE UNITThe invention relates to a method for treating substrates, which method comprises thefollowing steps: producing a liquid film on a local surface area of the substrates to betreated using a nozzle unit which comprises at least one elongate nozzle arrangment and also using an ultrasound or megasound transducer arrangement arranged next to thecontacting at least a part of the ultrasound transducer arrangement with the liquid film:and introducing ultrasound into the liquid film produced using the ultrasound tranducerarrangement.No figure
Patent SG-175074-A1 (SG)
Title: Additives for inhibiting gas hydrate formation
Inventor: LEINWEBER DIRK
Filed: 2010-05-19
Abstract: The invention relates to the use of polymers, containing between 1 and 100 mol % of structural units of the formula (1), wherein R1 means hydrogen or C1-C6 alkyl, A means C2-C4 alkylene groups, and B means C2-C4 alkylene groups, with the stipulation that A is different from B, and x and y mean an integer from 1 to 100 independent of each other, in amounts of 0.01 to 2 wt % relative to the water phase, as gas hydrate inhibitors.
Patent SG-175371-A1 (SG)
Title: An improved means of pipe handling
Inventor: MILLAR ROBERT
Filed: 2010-04-27
Abstract: An apparatus to transfer a pipe length between a well bore and a storage location, the apparatus comprising a first support means (12A, 12B) mounted for linear movement in a first horizontal direction, a second support means (15), operably mounted to the first support means (12A, 12B) and mounted for linear movement in a vertical direction; a support boom (18) pivotally mounted to the second support means (15) and having gripping means (19) to retain a pipe section, the support boom (18) being pivotable to move the gripping means (19) in a substantially horizontal direction, perpendicular to the first horizontal direction.
Patent SG-176748-A1 (SG)
Title: Method of reducing mapping of an electrodepositable coating layer
Inventor: KAYLO ALAN J
Filed: 2010-06-15
Abstract: The present invention is directed to a method for coating a substrate with a variety of coating compositions thereby reducing mapping of a coating composition deposited onto the substrate. In certain embodiments, the present invention is directed to the deposition of a zirconium based pretreatment composition onto a substrate with the subsequent deposition of an electrodepositable coating composition, which comprises a soluble alkaline earth metal ion, onto the pretreatment composition. The present invention is also directed to a coating system comprising various layers deposited from the coating compositions disclosed herein.
Patent SG-179191-A1 (SG)
Title: Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
Inventor: DANHOF IVAN E
Filed: 2010-09-17
Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
Patent SG-186321-A1 (SG)
Title: Needle shield for a safety device, safety device and injection device
Inventor: ROBERTS GARETH
Filed: 2011-06-21
Abstract: A needle shield (1.1) comprising at least two different plastic materials of different flexibility and a central aperture (1.1.3) of variable diameter (D1, D2). The central aperture (1.1.3) comprises a first diameter (D1) for retaining a needle cap (2.2) therein. The diameter of the central aperture (1.1.3) changes upon removal of the needle cap (2.2) from the first diameter (D1) to a second diameter (D2) by virtue of a memory effect of the material of the needle shield (1.1). The needle shield (1.1) is made by an injection moulding process.
Patent WO-2014065757-A1 (WO)
Inventor: NAVARSETE JULIA
IPC: B01D61/12
Filed: 2013-10-25
Abstract: Method and system for treating a liquid medium by reverse osmosis In a method for treating a liquid medium by reverse osmosis in a cyclic process, the pressure to the upstream side of the reverse osmosis membrane is generated by transferring the power of a basically free-falling weight to a hydraulic cylinder which generates the high pressure needed to overcome the osmotic pressure of the liquid medium. In a system, a movable vessel (5) containing a weight medium is provided capable of travelling vertically between an initial and terminal position. The power thereby generated is transmitted to a hydraulic cylinder (10)containing the liquid medium which is subjected to a high pressure and delivered to the upstream side of a reverse osmosis unit (14). At the end of process cycle the weight medium is released from the weight vessel (5). A following cycle is initiated by once more filling the weight vessel (5) with the weight medium and refilling the hydraulic cylinder (10) with untreated liquid medium.
Patent SG-188097-A1 (SG)
Title: Process and apparatus for producing a high polyphenol-containing composition
Inventor: HANAMURA SATOSHI
Filed: 2009-02-06
Abstract: PROCESS AND APPARATUSFOR PRODUCING A HIGH POLYPHENOL-CONTAINING COMPOSITIONAn object is to provide a process for producing, simply and effectively, a high polyphenol-containing composition, in5 particular, a composition the cacao polyphenol content is high while the theobromine content is low.The polyphenol-containing composition producing process comprises the following steps: (a) performing an extraction of a polyphenol-containing plant or a processed product thereof10 with a solvent, to obtain a crude polyphenol extract; (b) applying the crude polyphenol extract to a cation exchange resin subjected beforehand to hydrogen ion substitution, andsubsequently passing a first solvent containing no ionic substance through the cation exchange resin, to obtain a first15 polyphenoleluate; (c) passing the first polyphenol eluate again through a cation exchange resin subjected beforehand to hydrogen ion substitution, and then passing a second solvent containing no ionic substance through the cation exchange resin, to obtain a second polyphenol eluate; and (d) concentrating or drying the20 second polyphenol eluate. The process makes it possible to yield a polyphenol-containing composition that the polyphenol content. in solid content is 33% or more by weight, and the theobromine content is 1% or less by weight.FIG,
Patent SG-188137-A1 (SG)
Title: Methods and apparatus for changing area ratio in a plasma processing system
Inventor: DHINDSA RAJINDER
Filed: 2009-02-06
Abstract: METHODS AND APPARATUS FOR CHANGING AREA RATIO IN A PLASMA PROCESSING SYSTEMA plasma processing system having an upper electrode and a lower electrode. The upper electrode and lower electrode form two regions with different gaps. By moving one or both of the upper electrode and the lower electrode, it is possible to vary the ratio area of RF coupling depending on whether plasma is permitted to sustain in the first region or in both the first region and the second region.FIG 5
Patent SG-190727-A1 (SG)
Title: Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
Inventor: IGAWA TOMOYUKI
Filed: 2011-11-30
Abstract: 2085An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times ofantigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for10 improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having anincreased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen 15 binding molecules, and methods for producing them. The present inventors revealed that theabove objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.(No Suitable Figure)
Patent SG-192433-A1 (SG)
Title: Method for producing hydroxylated adamantane using cytochrome p450
Inventor: TOMIKAWA TAIJIRO
Filed: 2008-09-25
Abstract: AbstractMETHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450Disclosed is a method for producing a hydroxylated form of a compound having an adamantane skeleton, which is useful as an intermediate for functional resins and pharmaceutical products, with high yield and at low cost.Specifically, a hydroxylated form of a compound having an adamantane skeleton can be obtained by using cytochrome P450. More specifically, an N-(5-hydroxy-2-adamantyp-benzamide derivative can be produced by hydroxylating an N-(2-adamantyD-benzamide derivative.Figure for publication: None
Patent SG-191762-A1 (SG)
Title: Ligands that bind tgf-beta receptor ii
Inventor: BEATON ANDREW
Filed: 2012-01-04
Abstract: The disclosure provides an anti -TGFbetaRII immunoglobulin single variable domain. Suitably, an anti -TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO: 1-38, 204, 206, 208, 214, 234, 236, 238, 240, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289 or 291 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
Patent SG-192567-A1 (SG)
Title: Information processing apparatus, information processing method, and program
Inventor: ENOHARA TAKAAKI
Filed: 2012-12-20
Abstract: An information processing apparatus (30) iscommunicatively connected to a plurality of image sensors (10) that capture images of surroundings of a control5 target device (20) which is to be a target of power controlling. The information processing apparatus includes: an attribute information generation unit (313) that generates, by using the images captured by each of theimage sensors, attribute information of the control target10 device (20) which is under jurisdiction of at least one ofthe image sensors (10); and a management unit (341 or 342) that manages the attribute information of the controltarget device (20) generated by the attribute information generation unit (313) in association with the control15 target device (20) and the at least one of the image sensors (10) having jurisdiction over the control target device (20).
Patent SG-192268-A1 (SG)
Title: Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
Inventor: WILSON JAMES M
Filed: 2012-02-17
Abstract: A method of altering the targeting and/or cellular uptake efficiency of an adeno- associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered.
Patent SG-195651-A1 (SG)
Title: Novel method for preparing granulates of active principles, and granulates obtained thereof
Inventor: LEBON CHRISTOPHE
Filed: 2009-11-13
Abstract: 26NOVEL METHOD FOR PREPARING GRANULATES OF ACTIVE PRINCIPLES, AND GRANULATES OBTAINED THEREOFThe present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.No suitable figure
Patent WO-2018080393-A1 (WO)
Title: Oligonucléotides antisens
Inventor: SURANA UTTAM
IPC: A61P35/00
Filed: 2017-10-16
Abstract: La présente invention concerne des oligonucléotides antisens pour moduler l'activité de la glycine décarboxylase (GLDC). En particulier, la présente invention concerne des oligonucléotides antisens capables d'induire un saut d'exon d'ARN. L'invention concerne également des compositions pharmaceutiques, des kits et des méthodes de traitement du cancer et d'induction de saut d'exon à l'aide desdits oligonucléotides antisens. De plus, l'invention concerne une méthode d'aide à la catégorisation ou à la détermination du pronostic d'un cancer ou dans la sélection d'une stratégie thérapeutique pour un patient atteint d'un cancer, sur la base de l'évaluation du niveau d'acide nucléique, de protéine ou d'activité de la GLDC, dans un échantillon issu du patient.
Patent WO-2019132764-A1 (WO)
Inventor: SU LE
IPC: H04L9/32
Filed: 2017-12-26
Abstract: A traceback solution is provided. For a network of autonomous systems, the traceback solution traces the autonomous system path taken by traffic flows. Every link in the traceback path is created, verified, and audited by autonomous systems. Multiple autonomous systems may take part in the process, making the system robust against fake information. The database used to store the validated traceback paths is a decentralized and distributed storage. Multiple copies of the database may be maintained by the network of autonomous systems. The database may be accessible by any participating autonomous system; and is not accessible from outside the network of autonomous systems. The traceback solution achieves both validation and non-repudiation property among the ASes. The traceback solution mitigates some important attack scenarios that might be targeted specifically at the traceback solution.
Patent WO-2021107869-A1 (WO)
Inventor: MIGUEL SÁNCHEZ JAVIER
IPC: G06N3/02
Filed: 2020-11-24
Abstract: A method of preparing devices comprising respective spectrometer modules to perform one or more specific applications, the spectrometer modules being part of a batch of spectrometer modules. The method comprises, for the or each said application, performing optical measurements using a subset of said batch of spectrometer modules to generate respective sets of wavelength-versus-operating parameter data, and using said data to train a neural network to successfully perform the or each application. The trained neural network is stored in memories of each of said devices, wherein said devices are configured to perform the or each said application by generating spectral data using respective spectrometer modules and applying that spectral data or data derived therefrom to the stored neural network.
Patent WO-2008060250-A1 (WO)
Title: Raccord de tuyau pour aspirateur
Inventor: MAGAJNA Andrej
IPC: A47L9/24
Filed: 2007-10-10
Abstract: La présente invention concerne un raccord (8) permettant de relier un tuyau d'aspiration (51) à un aspirateur (14). D'après l'invention, le raccord (8) est fixé de façon permanente, orientée ou rotative au tuyau d'aspiration (51), la fixation du tuyau d'aspiration (51) à l'aspirateur (14) étant assurée par le biais de deux éléments de verrouillage (18), situés au niveau du corps du raccord (33), chacun des deux éléments de verrouillage étant maintenu dans sa position extérieure par un ressort en porte-à-faux préchargé (45). Le déboîtement du raccord de tuyau s'effectue par un mouvement axial du glissoir (31) dans la direction opposée de l'aspirateur (14), de telle manière que ledit glissoir (31), par contact de glissement entre son bord de périmètre (90) et la collerette d'encastrement (19), libère les deux éléments de verrouillage (18) de leur position externe, libérant ainsi le système d'emboîtement entre les deux dents de verrouillage (84) et les deux nervures de verrouillage (55).
Patent WO-2013176628-A1 (WO)
Inventor: CAJHEN TADEJ
IPC: F21V7/00
Filed: 2012-10-26
Abstract: By taking into consideration a combination of all features of a reflector (2) and a light source (3), which are included in the independent claim, the prescribed requirements in view of achieving a bright/dark border and preventing dissipation of light in undesired direction are fulfilled despite to using cheap conventional "single chip" or "chip size or "single chip based" LEDs (3') instead of "multi chip" LEDs.
Patent WO-2014104983-A1 (WO)
Title: Process and apparatus for measuring of thickness of a probe during a tension test
Inventor: JAPELJ BLAZ
IPC: G01B11/16
Filed: 2012-12-27
Abstract: Apparatus for measuring of thickness of a probe (2) during a tension test comprises a tensioning device (1), which is furnished with a fixed jaw (11) and a displaceable jaw (12), which are arranged above each other and are adapted for clamping and tensioning of each disposable standardized probe (2), as well as a video camera (3), which is arranged in the area of said tensioning device (1) at appropriate distance apart of the probe (2), so that the optical axis (30) of the video camera (3) extends towards the longitudinal axis (20) of the probe (2) and rectangular with respect to said longitudinal axis (20) of the probe (2). The apparatus further comprises a screen (5), which forms a contrast background behind the probe (2) and is with respect to said video camera (3) arranged on the opposite side of the probe (2), and moreover also a computer (4), which is adapted for retrieving, saving and processing of data received from the video camera (3).
Patent WO-2014104986-A1 (WO)
Title: Video extensiometer
Inventor: JAPELJ BLAŽ
IPC: G01B11/16
Filed: 2013-12-23
Abstract: Video extensiometer, namely apparatus for measuring of extension of a probe (2) during a tension test, comprising a tensioning device (1) furnished with a fixed jaw (11) and a movable jaw (12) which are adapted to hold and load each probe (2), a video camera (3) directed towards said probe (2), a contrast screen (5) located behind said probe (2) opposite to said camera (3), as well as a computer (4) adapted for recording pictures of the probe (2) and processing the data related to said pictures in accordance with a pre-defined algorithm for the purposes to calculate relative elongation of the tensioned and extended probe (2).
Patent TN-2011000062-A1 (TN)
Title: Pyrrolopyrimidine compounds of cdk inhibitors
Inventor: BRAIN CHRISTOPHER THOMAS
IPC: C07D487/04
Filed: 2011-02-04
Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
Patent TN-2011000131-A1 (TN)
Title: Amides utiles en therapie
Inventor: WAKENHUT FLORIAN
IPC: C07D487/04
Filed: 2011-03-14
Abstract: un composé de formule (I), ou un de ses sels ou produits de solvatation pharmaceutiquement acceptables formule (I) dans laquelle, R1 et R2 représentent chacun indépendamment H, un groupe halogèno, CF3, alkyle en C1 à C3 ou alkoxy en C1 à C3; R3 représente un groupe alkyle en C1 à C6, cycloalkyle en C3 à C6, phényle (facultativement substitué avec un ou plusieurs substituants choisis chacun independament parmi des substituants Ra ) ou HET( facultativement substitué avec un ou plusieurs substituants OH, OXO et alkyle en C1 à C4 ) , R4 represente H ou un groupe alkyle en C1 à C3 , R5 represente un groupe alkyle en C1 à C6 ( facultativement substitué avec un ou plusieurs substituants choisis chacun independament parmi des substituants Rb ) , cycloalkyle en C3 à C6 ( facultativement substitué avec un ou plusieurs substituants choisis independament entre des substituantsOXO ET OH ou HET2 ( facultativement substitué avec un ou plusieurs substituants choisis chacun independamment parmi des substituants rd; un atome d' oxygene ou un atome de soufre ou (c) l atome d 'oxygene ou l atome de soufre ( facultativement substitué avec un ou plusieurs substituants choisis chacun independamment entre des substituants OH ,OXO ou alkyle en c1 à c4 ) et R6 represente un groupe alkyle en c1 à c3 ( facultativement substitué avec un ou plusieurs substituants choisis independamment parmi des substituants R F) , cycloalkyle en c3 à c5 ( facultativement substitué avec un ou plusieurs substituants halogeno ) CN ou halogeno , ou rf represente un groupe halogen oou phenyle , et des compositions des procedes pour la preparation de et les utilisations de ceux - ci , par exemples dans le traitement de l 'endometriose ou des fibromes uterins,